证券代码：688098 证券简称：申联生物 公告编号：2023-031 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 申联生物医药（上海）股份有限公司 重要内容提示： 关于参加 2023 年半年度制药及生物制品行业 会议线上交流时间：2023 年 9 月 7 日(星期四)下午 13:00-15:00 集体业绩说明会的公告 本次业绩说明会以网络文字互动形式召开，公司将针对 2023 年半年度的经 营成果及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许的 范围内就投资者普遍关注的问题进行回答。 二、说明会召开的时间、地点 （一）会议线上交流时间：2023 年 9 月 7 日下午 13:00-15:00 （二）会议召开方式：网络文字互动 （三）网络文字互动平台：上海证券交易所上证路演中心（网址： http://roadshow.sseinfo.com/） 会议召开方式：网络文字互动 线 上 文 字 互 动 平 台 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： http://roadsho ...

二、监事会会议审议情况 证券代码：688098 证券简称：申联生物 公告编号：2023-030 申联生物医药（上海）股份有限公司 第三届监事会第七次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 申联生物医药（上海）股份有限公司（以下简称"公司"）第三届监事会第 七次会议于 2023 年 8 月 29 日以现场结合通讯方式召开，本次会议通知已于 2023 年 8 月 19 日以邮件方式送达公司全体监事。本次会议由监事会主席叶尔阳先生 主持，会议应出席监事 3 名，实际出席监事 3 名，会议的召集和召开程序符合 《中华人民共和国公司法》和《公司章程》等相关规定，会议形成的决议合法、 有效。 （一）审议通过《关于审核<2023 年半年度报告>及其摘要的议案》 监事会审核了公司《2023 年半年度报告》及其摘要，了解并监督了半年度报 告的编制及审议程序，全体监事列席董事会并了解董事会对半年度报告的审议情 况。监事会认为《2023 年半年度报告》的编制、审核以及董事会的审议程序符合 法律法规、 ...

证券代码：688098 证券简称：申联生物 公告编号：2023-029 申联生物医药（上海）股份有限公司 2023 年 1-6 月募集资金存放与使用情况的专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 申联生物医药（上海）股份有限公司（以下简称"公司"）董事会根据中国证券 监督管理委员会(以下简称"证监会")《上市公司监管指引第 2 号——上市公司募集 资金管理和使用的监管要求（2022 年修订）》及《上海证券交易所科创板上市公司 自律监管指引第 1 号——规范运作》等相关法律、法规及规范性文件的规定，编制 了 2023 年 1-6 月关于公司首次公开发行 A 股股票募集资金存放与实际使用情况的 专项报告。现将截至 2023 年 6 月 30 日公司募集资金存放与实际使用情况专项说明 如下： 一、募集资金基本情况 （一）实际募集资金金额、资金到账时间 根据证监会作出的《关于同意申联生物医药（上海）股份有限公司首次公开发 行股票注册的批复》（证监许可[2019]1743 号），同意公司向社会公开发行人民币普 通股（ ...

公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 申联生物医药（上海）股份有限公司（以下简称"公司"）近日通过了农业 农村部畜牧兽医局兽药临床试验质量管理规范（GCP）的监督检查。公司本次通 过监督检查并符合兽药临床试验质量管理规范（GCP）要求的试验项目信息如下： 公司本次通过兽药临床试验质量管理规范（GCP）监督检查，短期内对公司 申联生物医药（上海）股份有限公司 自愿披露关于通过农业农村部兽药 GCP 监督检查的 公告 | 分类 | 试验项目 | 动物实验场所名称 | | --- | --- | --- | | 兽药临床试 | 猪安全性试验（兽用生物制 | 永登县剑锋养殖场、三门峡市为民实业有 | | | 品） | 限公司、成都茵莱牧业专业合作社 | | 验质量管理 规范（GCP） | 猪有效性试验（兽用生物制 | 永登县剑锋养殖场、三门峡市为民实业有 | | | | 限公司、成都茵莱牧业专业合作社、申联 | | | 品） | 生物医药（上海）股份有限公司兰州分公 | | | | 司（动物实验室） | 证券代码：6880 ...

证券代码：688098 证券简称：申联生物 公告编号：2023-025 申联生物医药（上海）股份有限公司 关于参加 2022 年度生物制品专场集体业绩说明会的 公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 会议线上交流时间：2023 年 6 月 14 日(星期三)下午 14:00-15:00 会议召开方式：视频和线上文字互动 视频和线上文字互动平台：上海证券交易所上证路演中心（网址： http://roadshow.sseinfo.com/） 投资者可于 6 月 13 日(星期二)16:00 前通过邮件、电话将需要了解和关 注的问题提前提供给公司。公司将在文字互动环节对投资者普遍关注的问题进 行回答。 申联生物医药（上海）股份有限公司（以下简称"公司"）已于 2023 年 4 月 27 日发布公司《2022 年年度报告》，为便于广大投资者更全面深入地了解公司 2022 年年度经营成果、财务状况等信息，公司参与了由上交所主办的 2022 年度 生物制品专场集体业绩说明会，此次活动将采用视频和网络文字互 ...

Financial Performance - The company's operating revenue for 2022 was ¥328.59 million, a decrease of 8.32% compared to ¥358.43 million in 2021[23]. - The net profit attributable to shareholders for 2022 was ¥61.10 million, down 44.56% from ¥110.20 million in 2021[23]. - Basic earnings per share for 2022 were ¥0.15, a decline of 44.44% from ¥0.27 in 2021[24]. - The company's cash flow from operating activities decreased by 89.92% to ¥9.09 million, significantly impacted by delayed sales collections due to economic downturns[26]. - The company achieved an annual revenue of 329 million yuan, a decrease of 8.32% compared to the previous year[41]. - The company reported a total revenue of 18,640.00 million RMB for the year, with a net profit of 3,308.23 million RMB, reflecting a significant increase in performance[88]. - The company’s operating cost was CNY 81,395,617.32, down 6.43% year-on-year, with the main business cost decreasing by 6.47%[128]. - The gross margin for the main business was 75.19%, a decrease of 0.50 percentage points compared to the previous year[130]. - The sales revenue from government procurement was CNY 313,773,594.69, with a slight increase of 2.76% year-on-year[130]. - The market sales revenue dropped to CNY 14,100,343.40, a decrease of 73.11% compared to the previous year[130]. Research and Development - The company has developed unique vaccine technologies, including the i-Molsta and i-Nada, aimed at enhancing vaccine stability and efficacy[13]. - The company's R&D expenses increased by ¥4.09 million, representing 20.56% of operating revenue, up from 19.14% in 2021[24]. - The total R&D investment for the year was ¥67,545,075.67, a decrease of 1.52% compared to the previous year, with a ratio of R&D investment to operating income at 20.56%, up by 1.42 percentage points[85]. - The company has established multiple vaccine technology platforms, including inactivated vaccine, synthetic peptide vaccine, virus-like particle vaccine, and in vitro diagnostic technology platforms, enhancing its core competitiveness[76]. - The company is actively developing new veterinary drugs, including a bivalent inactivated vaccine for foot-and-mouth disease and a trivalent inactivated vaccine for swine diseases, which are currently in the registration phase[94]. - The company is focusing on independent innovation and increasing R&D investment in the veterinary biological products sector[82]. - The company has ongoing projects for vaccines against various diseases, including the African swine fever virus and foot-and-mouth disease[156]. - The company’s R&D investment accounted for 20.56% of operating revenue, which is significantly higher than the industry average of 15.04%[162]. - The company has not canceled any major R&D projects during the reporting period, indicating stability in its development pipeline[158]. Product Development and Innovation - The company launched the "Lian Yuan Jing" vaccine by the end of 2022, marking a significant product introduction[25]. - The company has completed the development of the bivalent inactivated vaccine for foot-and-mouth disease in cattle and sheep and submitted the product approval application[38]. - The company has developed a series of new inactivated vaccines utilizing advanced technologies, including gene engineering and high-efficiency suspension culture technology, addressing industry pain points[72]. - The company is actively advancing the development of mRNA vaccines and has made significant progress in laboratory research[38]. - The company has successfully launched the first-class new veterinary drug, a bivalent inactivated vaccine for foot-and-mouth disease (types O and A), which has received high customer recognition for its effectiveness and safety[72]. - The company has developed and obtained new veterinary drug registration certificates for multiple products, including a bivalent inactivated vaccine for foot-and-mouth disease, which has received approval for production[88]. - The company is expanding its product matrix to include a diverse range of veterinary products, contributing to the development of China's livestock industry[92]. - The company is developing a range of veterinary diagnostic products for major animal diseases, ensuring high sensitivity and specificity in its diagnostic kits[103]. - The company has received product approval for the pig circovirus type 2 subunit vaccine and is in the registration phase for several other vaccines, indicating a diverse product pipeline[78]. Corporate Governance and Compliance - The company is committed to maintaining high standards of corporate governance and transparency in its operations[8]. - The company has received a standard unqualified audit report from Da Hua Accounting Firm, ensuring the accuracy of its financial statements[6]. - The company’s board of directors and management have confirmed the authenticity and completeness of the annual report[5]. - The company emphasizes the importance of risk factors in its management discussion, urging investors to read the relevant sections carefully[5]. - The company has established a quality management system that complies with GMP and ISO9001 standards, enhancing overall quality control[42]. - The company has passed the biosecurity level three protection acceptance and strictly implements GMP management, maintaining controllable biosecurity risks[115]. - The company adheres to strict quality management practices, aligning with national veterinary drug regulations and international quality standards to ensure product quality[104]. Market Position and Strategy - The company is focused on expanding its market presence and enhancing its product offerings in the high-tech biomedical sector[2]. - The company is actively developing a comprehensive technical service and disease prevention solutions to enhance product penetration among end users[60]. - The company aims to optimize its service channels by establishing core service providers and benchmark customers to provide high-quality vaccine products and services to small and medium-sized farms nationwide[60]. - The company is recognized as a high-tech enterprise, benefiting from a reduced corporate income tax rate of 15% for three years, which could be impacted by future re-evaluations[120]. - The company is enhancing its marketing system to increase the market-oriented sales ratio, focusing on the sales of the "Taiji Lian" vaccine and the promotion of the new "Lian Yuan Jing" vaccine[187]. - The company is facing risks related to accounts receivable collection, particularly from government clients, which may be affected by economic downturns[119]. - The company is positioned in a technology-intensive industry with high barriers to entry, requiring significant investment in R&D and compliance with stringent safety and quality standards[69]. Talent and Management - The company implemented a talent strategy focused on optimizing the core management team and enhancing employee career development pathways[45]. - The number of R&D personnel decreased to 67, accounting for 18.36% of the total workforce, down from 23.23% in the previous year[90]. - The company has a core technical team consisting of Nie Dongsheng, Zhang Zhen, Yin Bo, and Ma Guijun, with Yin Bo being a new addition in 2023[200]. - The total pre-tax remuneration for the core technical personnel, including Ma Guijun, was 1 million yuan[200]. - Talent acquisition mechanisms are being improved to attract high-end talent in the biopharmaceutical industry, focusing on training mid-to-senior management personnel[192].

Financial Performance - The company's revenue for Q1 2023 was ¥81,851,831.18, representing a decrease of 8.08% compared to the same period last year[3] - Net profit attributable to shareholders was ¥15,867,632.60, down 33.69% year-on-year[3] - The company reported a net profit margin of approximately 22.0% for Q1 2023, compared to 28.0% in Q1 2022[16] - In Q1 2023, the company reported a net profit of CNY 15,867,632.60, a decrease of 33.5% compared to CNY 23,924,876.69 in Q1 2022[18] - Operating profit for Q1 2023 was CNY 19,162,338.23, down 33.2% from CNY 28,678,434.18 in the same period last year[20] - The company reported a total profit of CNY 19,111,308.51 in Q1 2023, a decrease of 33.1% from CNY 28,629,934.18 in Q1 2022[20] Research and Development - R&D expenses totaled ¥11,254,624.80, which is an increase of 10.54% compared to the previous year, accounting for 13.75% of revenue, up 2.32 percentage points[3] - The company is actively pursuing new technology and product development, with R&D expenses increasing significantly[6] - Research and development expenses increased to CNY 8,757,354.77, up 68.5% from CNY 5,196,621.48 in Q1 2022[20] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,600,170,365.42, a slight decrease of 0.31% from the end of the previous year[4] - Total assets as of March 31, 2023, were RMB 1,600,170,365.42, slightly down from RMB 1,605,083,700.71 at the end of 2022[13] - Total liabilities decreased to RMB 87,068,037.56 from RMB 108,209,232.05 at the end of 2022, a reduction of 19.5%[14] - Shareholders' equity increased to RMB 1,513,102,327.86 as of March 31, 2023, compared to RMB 1,496,874,468.66 at the end of 2022, an increase of 1.1%[14] Cash Flow - Cash and cash equivalents as of March 31, 2023, were RMB 45,884,713.20, down from RMB 52,742,562.11 at the end of 2022, representing a decrease of 13.4%[12] - Cash flow from operating activities showed a net outflow of CNY 32,986,013.65, an improvement from a net outflow of CNY 42,272,933.50 in Q1 2022[20] - Total cash and cash equivalents at the end of Q1 2023 were CNY 45,727,802.46, down from CNY 53,005,125.45 at the end of Q1 2022[21] - The company generated CNY 33,979,285.31 in cash from sales in Q1 2023, a significant increase from CNY 21,017,968.10 in Q1 2022, representing a growth of 61.2%[20] - Investment activities generated a net cash inflow of CNY 26,338,281.46 in Q1 2023, compared to CNY 51,106,906.26 in Q1 2022[21] Shareholder Information - The top shareholder, Yang Yufang, holds 21.93% of the shares, totaling 90,063,197 shares[8] - The basic earnings per share were ¥0.04, reflecting a decrease of 33.33%[3] - The basic earnings per share for Q1 2023 was CNY 0.04, down from CNY 0.06 in Q1 2022[18] Market and Sales - The company experienced a decline in sales due to delayed government procurement for foot-and-mouth disease vaccines, impacting revenue[6] - The company plans to focus on expanding its market presence and developing new products in the upcoming quarters[10]

Company Overview - Shunlian Bio is a high-tech enterprise specializing in the R&D, production, and sales of veterinary biological products, particularly foot-and-mouth disease (FMD) vaccines [1][2]. - The company holds 7 national new veterinary drug registration certificates, including 2 Class I new veterinary drugs, and has been granted 76 national patents, of which 27 are invention patents [2]. Product and Production Line - The company focuses on a dual-product strategy, with FMD vaccines as the main product and other animal vaccines and veterinary diagnostic reagents as supplementary [2]. - Shunlian Bio has developed a series of high-quality FMD synthetic peptide vaccines, including the first multi-valent synthetic peptide vaccine for pigs [2]. - The company has two production bases in Shanghai and Lanzhou, with production lines for inactivated vaccines and synthetic peptide vaccines that have passed GMP certification [2][3]. Recent Business Performance - In 2021, the company achieved a revenue of CNY 358.43 million, a year-on-year increase of 6.13%, with a compound annual growth rate of 18.83% over the past three years [3]. - The company sold over 3.2 billion doses of FMD vaccine products [3]. - R&D investment in 2021 totaled CNY 68.59 million, accounting for 19.14% of revenue, reflecting a year-on-year increase of 102.94% [3]. New Product Development - The new product "Taijilian," a bivalent inactivated vaccine for FMD, was launched in March 2021 and is expected to significantly enhance market share [3][4]. - The company is also developing several new products, including vaccines for porcine circovirus and swine fever, expected to be launched in the next 1-5 years [5]. Market Strategy and Future Outlook - The company plans to expand its market presence by enhancing sales capabilities and training for distributors, with a focus on large-scale breeding farms [4][5]. - The anticipated recovery of pig prices is expected to boost demand for vaccines, positively impacting the company's sales [4][7]. - The company aims to maintain steady growth while expanding into new vaccine products and markets, ultimately increasing shareholder returns [5][8].

Financial Performance - The company's revenue for Q3 2022 was ¥148,322,330.47, representing a year-over-year increase of 24.24%[4] - Net profit attributable to shareholders was ¥49,080,448.93, showing a slight increase of 3.39% compared to the same period last year[4] - The basic earnings per share for the quarter was ¥0.12, reflecting a decrease of 18.18% compared to the previous year[4] - Net profit for the third quarter of 2022 was ¥72,351,539.79, a decrease of 19.6% from ¥90,049,371.98 in the same quarter of 2021[18] - Basic earnings per share for the third quarter of 2022 were ¥0.18, down from ¥0.22 in the same period of 2021[18] - Total revenue for the first three quarters of 2022 reached ¥286,584,956.33, an increase of 5.4% compared to ¥272,415,976.87 in the same period of 2021[16] Research and Development - The total R&D expenditure for the quarter was ¥23,793,101.77, which is an increase of 117.73% year-over-year, accounting for 16.04% of total revenue[5] - Research and development expenses for the third quarter of 2022 were ¥26,393,024.56, an increase of 47.0% from ¥17,914,612.49 in the previous year[17] Assets and Liabilities - The company's total assets increased by 2.66% to ¥1,640,983,534.58 compared to the end of the previous year[5] - Total assets as of the end of the third quarter of 2022 amounted to ¥1,640,983,534.58, compared to ¥1,598,464,318.21 at the end of the third quarter of 2021[15] - Total liabilities increased to ¥126,878,877.83 in the third quarter of 2022, compared to ¥125,476,791.81 in the same period of 2021[15] Cash Flow - Cash flow from operating activities showed a significant decline of 395.61% year-to-date, primarily due to delayed payments from local animal epidemic prevention departments[8] - The net cash flow from operating activities was -41,221,111.53, a decrease from 13,944,598.26 in the previous quarter[21] - Cash inflow from investment activities totaled 1,570,790,119.34, compared to 2,723,589,766.03 in the prior quarter[21] - The net cash flow from investment activities was 59,062,990.00, a significant improvement from -12,187,583.03 in the previous quarter[21] - Cash outflow from financing activities was 36,932,899.32, slightly lower than 40,913,135.64 in the previous quarter[22] - The ending balance of cash and cash equivalents was 25,280,141.36, down from 82,949,840.46 in the previous quarter[22] Shareholder Information - The company reported a total of 10,614 common shareholders at the end of the reporting period[10] - The top shareholder, Yang Yufang, holds 90,063,197 shares, representing 21.93% of the total shares[10] - The total number of shares held by the top 10 shareholders accounts for 35.82% of the company's total shares[11] Inventory and Receivables - The total inventory as of September 30, 2022, was RMB 105,999,376.26, showing a slight increase from RMB 103,420,614.45 at the end of 2021[13] - Accounts receivable increased significantly to RMB 298,314,451.76, up from RMB 151,014,971.48, indicating a growth of about 97.8%[13] Other Information - The company has not disclosed any significant new product developments or technological advancements during the reporting period[12] - There were no significant mergers or acquisitions reported in the third quarter[12] - The company has not provided specific future guidance or outlook for the upcoming quarters[12]

Financial Performance - The company's operating revenue for the first half of 2022 was ¥138,262,625.86, a decrease of 9.65% compared to ¥153,028,601.14 in the same period last year[20] - The net profit attributable to shareholders for the first half of 2022 was ¥23,284,086.22, down 47.58% from ¥44,421,029.76 in the previous year[20] - The net cash flow from operating activities was negative at -¥35,431,206.24, compared to a positive cash flow of ¥2,684,655.94 in the same period last year, representing a decline of 1,419.77%[20] - The total assets at the end of the reporting period were ¥1,578,341,221.32, a decrease of 1.26% from ¥1,598,464,318.21 at the end of the previous year[20] - The net assets attributable to shareholders decreased by 0.62% to ¥1,469,638,562.36 from ¥1,478,877,320.58 at the end of the previous year[20] - Basic earnings per share for the first half of 2022 were ¥0.06, down 45.45% from ¥0.11 in the same period last year[21] - The diluted earnings per share were also ¥0.06, reflecting the same decline of 45.45% compared to the previous year[21] - The company's revenue decreased by 9.65% year-on-year, primarily due to the sluggish market conditions in the pig farming industry, leading to a decline in product sales[23] - Net profit attributable to shareholders decreased by 47.58% year-on-year, while the net profit after deducting non-recurring gains and losses fell by 54.44%[23] - The basic and diluted earnings per share dropped by 45.45% compared to the same period last year, mainly due to the decline in revenue and high fixed asset depreciation costs associated with the new product "Taiji Lian" not reaching its designed capacity[23] Research and Development - The research and development expenditure accounted for 18.13% of operating revenue, a decrease of 1.33 percentage points from 19.46% in the previous year[21] - The company has established four major technology platforms: synthetic peptide vaccine technology, inactivated vaccine technology, virus-like particle vaccine technology, and in vitro diagnostic technology[70] - The company is recognized as a leading entity in the research and development of synthetic peptide vaccines for foot-and-mouth disease, focusing on the latest epidemic strains and technological advancements[70] - The company has developed the first domestic multi-valent synthetic peptide vaccine for foot-and-mouth disease (FMD) in pigs, which includes the O-type and A-type vaccines[49] - The company is actively increasing its research and development efforts for multivalent and multi-target vaccines to meet the evolving demands of disease prevention in livestock[48] - The company has achieved a 6.79% increase in expensed R&D investment, totaling approximately ¥16.14 million, while capitalized R&D investment decreased by 39.12% to approximately ¥8.93 million[61] - Total R&D investment amounted to ¥25,068,739.52, a decrease of 15.82% compared to the previous year[62] - The company has received a total of 3 new intellectual property rights during the reporting period, including 1 invention patent and 1 utility model patent[59] - The company is focusing on enhancing its "vaccine + diagnostics" product development pipeline, which is expected to strengthen its competitive position in the market[57] Market Position and Industry Overview - The company specializes in the research, production, and sales of veterinary biological products, focusing on foot-and-mouth disease vaccines and veterinary diagnostic products[28] - The company is a designated producer of foot-and-mouth disease vaccines, which are critical for preventing outbreaks that can cause significant economic losses in the livestock industry[29] - The main products include various types of foot-and-mouth disease vaccines and diagnostic kits for African swine fever, indicating a focus on addressing critical animal health issues[31] - The company achieved a sales revenue of 338 million yuan in 2020, ranking fifth in the domestic pig biological products market with a market share of 5.0%[41] - The average gross profit margin for the veterinary biological products industry was 63.67% in 2020, with an asset profit rate of 20.38%[38] - The company is a leading player in the domestic foot-and-mouth disease (FMD) peptide vaccine sector, being one of the first to develop and industrialize this vaccine globally[46] - The company has established stable long-term relationships with suppliers to ensure a steady supply of raw materials, which supports its production capabilities[33] - The company primarily sells foot-and-mouth disease vaccines through government tender procurement and market-oriented sales, with annual government tenders typically held 1-2 times based on local epidemic prevention needs[35] Environmental and Social Responsibility - The company has established and effectively operates its environmental protection facilities, meeting all discharge requirements for waste gas, wastewater, noise, and solid waste[131] - The total wastewater discharge in the first half of 2022 from the Shanghai outlet was 689.4 tons, with no exceedances in pollutant discharge limits for key pollutants[131] - The company has conducted regular drills for its emergency response plan to ensure preparedness for environmental incidents[141] - The company organized over 60 training sessions and served more than 2,000 farming households, impacting over 20 provinces in animal disease prevention[149] - A total of 4.85 million yuan was donated to the Gansu Poverty Alleviation Foundation for purchasing 100 sets of sports equipment for rural students[149] - The company donated 280,000 yuan for purchasing 59,000 pieces of medical protective equipment to support COVID-19 relief efforts in Shanghai[149] Governance and Compliance - The company has established strict guidelines to avoid related party transactions and will comply with relevant laws and regulations to protect the interests of shareholders[156] - The company has a lock-up period for shares held by executives, which lasts for 36 months post-IPO, with restrictions on transferring shares during this time[157] - The company will ensure that any related party transactions are disclosed and conducted in accordance with legal requirements to avoid harming the interests of the company and its shareholders[156] - The company has committed to avoiding any competitive activities with its subsidiaries during and after its tenure[180] - The company will strictly adhere to all public commitments made during the IPO process, with measures in place to address any failures to fulfill these commitments[176] Future Plans and Investments - The company plans to invest 34.15 million yuan in constructing animal live and inactivated vaccine workshops, with an expected annual sales increase of 32 million yuan and an annual profit increase of 9.6 million yuan[117] - The company aims to enhance its market competitiveness by focusing on technological innovation and quality improvement rather than traditional price competition[82] - The company will continue to invest in R&D and market expansion, focusing on improving product quality and production efficiency to strengthen competitiveness and increase market position[172] - The company aims to diversify its product offerings and business direction through the development of new vaccine technologies[192] - The company is advancing multiple vaccine projects, with several in the new veterinary drug registration and clinical trial stages[87]